Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy (MESOIMMUNE)

March 5, 2021

Primary Outcome Measures

  1. Disease control [ Time Frame: 12 weeks ]
    Disease control rate at 12 weeks

Secondary Outcome Measures

  1. Survival with anti-PD1/PDL1 immunotherapy [ Time Frame: 12 weeks ]
    Overall survival from treatment with anti-PD1/PDL1 immunotherapy
  2. Duration of treatment [ Time Frame: 12 weeks ]
    Duration of treatment with PD1/PDL1 immunotherapy
  3. Survival [ Time Frame: 12 weeks ]
    Overall survival from the start of the first treatment
  4. Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by previous immunotherapy [ Time Frame: 12 weeks ]
    Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by following data: which immunotherapy, date of treatment beginning/end
  5. Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by adverse event [ Time Frame: 12 weeks ]
    Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by following data: numbers of treatment related adverse events from CTCAE v4.0
  6. Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by remarkable event [ Time Frame: 12 weeks ]
    Tolerance of treatment with PD1/PDL1 immunotherapy evaluated by following data: date of best response, date of progression, date of death)
  7. To identify factors predictive of treatment response by immunotherapy in responder patients [ Time Frame: 12 weeks ]
    Identify factors predictive of treatment response by immunotherapy in responder patients by collecting following data: Demographics data, treatment data, and blood test results and histological data
  8. To identify factors predictive of the response of immunotherapy treatment of progressive patients [ Time Frame: 12 weeks ]
    Identify factors predictive of treatment response by immunotherapy of progressive by collecting following data: Demographics data, treatment data, and blood test results and histological data
  9. To identify factors predictive of the response of immunotherapy treatment of all patients [ Time Frame: 12 weeks ]
    Identify factors predictive of treatment response by immunotherapy of all patients by collecting following data: Demographics data, treatment data, and blood test results and histological data
  10. To identify factors predictive of the response of immunotherapy treatment according to follow-up treatment [ Time Frame: 12 weeks ]
    Identify factors predictive of treatment response by immunotherapy according to type of treatment after PD1/PDL1 immunotherapy

Inclusion Criteria

  • Patient over 18 years of age,
  • Diagnosis of malignant pleural mesothelioma affirmed by the anatomo-pathological analysis report of a histological sample of the tumour (re-read by MESOPATH).
  • Patient who has received at least one injection of anti-PD1 or anti-PDL1 antibodies

Exclusion Criteria

  • Explicit refusal by the patient to collect data
CONTACT INFORMATION

Name*
Address*
Have you received a diagnosis?*
DIAGNOSIS
MM slash DD slash YYYY
This field is for validation purposes and should be left unchanged.

Quick Facts

Accepts Healthy Volunteers
Ages Available for Study
ClinicalTrials.gov Identifier
Collaborators
Contacts(s)
Location(s)
Estimated Enrollment
Estimated Study Start Date
Estimated Primary Completion Dates
Full Title
Genders Eligible for Study
Investigator(s)
Last Updated
Other Contact